Skip to main navigation menu Skip to main content Skip to site footer

MYOCARDIAL INFARCTION AND SOME CORONARY ARTERY DISEASE ISSUES AFTER COVID 19

Abstract

Over the past almost 3 years COVID 19 has became most problematic disease around the world. It can be explained with difficult mutations with time to time it originating and troublesome creating proper vaccines. However nowadays scientists has launched so many ways to conquer the virus. Patients infected with the virus SARS-CoV-2 and its clinical disease COVID-19 are often minimally symptomatic or asymptomatic. More severe presentations include pneumonia and acute respiratory distress syndrome. [11]In some patients, the heart may be affected, and this can occur in individuals with or without a prior cardiovascular diagnosis. Evidence of myocardial injury, as defined as an elevated troponin level, is common among patients hospitalized with COVID-19, with putative causes including stress cardiomyopathy, hypoxic injury, ischemic injury (caused by cardiac microvascular damage or epicardial coronary artery disease), and systemic inflammatory response syndrome (cytokine storm). A minority of patients with an elevated troponin level present with symptoms and signs suggestive of an acute coronary syndrome.

Keywords

COVID 19, SARS-CoV-2 virus, myocardial infarction, coronary artery disease, myocarditis,

DOWNLOAD PDF CERTIFICATE

References

  1. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061.
  2. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol 2020; 5:831.
  3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.
  4. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109:531.
  5. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091.
  6. Garcia S, Albaghdadi MS, Meraj PM, et al. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic. J Am Coll Cardiol 2020; 75:2871.
  7. De Filippo O, D'Ascenzo F, Angelini F, et al. Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy. N Engl J Med 2020; 383:88.
  8. Solomon MD, McNulty EJ, Rana JS, et al. The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction. N Engl J Med 2020; 383:691.
  9. De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J 2020; 41:2083.
  10. Garcia S. Reduction in ST-segment elevation. J Am Coll Cardiol 2020; :2871.
  11. Taxirovich, A. S. (2023). The Main Etiological Factors, Methods of Prevention and Treatment of Meningitis. Inter-national Journal of Scientific Trends, 2(2), 141-148.
  12. Xiang D, Xiang X, Zhang W, et al. Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China. J Am Coll Cardiol 2020; 76:1318.
  13. Mohammad MA, Koul S, Olivecrona GK, et al. Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic. Heart 2020; 106:1812.
  14. De Luca G, Verdoia M, Cercek M, et al. Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. J Am Coll Cardiol 2020; 76:2321.
  15. Libby P, Loscalzo J, Ridker PM, et al. Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. J Am Coll Cardiol 2018; 72:2071.
  16. Modin D, Claggett B, Sindet-Pedersen C, et al. Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. Circulation 2020; 142:2080.
  17. Bangalore S, Sharma A, Slotwiner A, et al. ST-Segment Elevation in Patients with Covid-19 - A Case Series. N Engl J Med 2020; 382:2478.
  18. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 2020; 324:799.
  19. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 2021; 398:599.
  20. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19): China. China CDC Weekly 2020; 2:113.
  21. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239.
  22. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21:335.
  23. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:145.
  24. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708.
  25. Chow YW, Pietranico R, Mukerji A. Studies of oxygen binding energy to hemoglobin molecule. Biochem Biophys Res Commun 1975; 66:1424.
  26. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5:811.
  27. Author similar topic fromUptodate program: Duane S Pinto MPH,MD

Downloads

Download data is not yet available.